| Literature DB >> 26910372 |
Jin Fan1, Wen Sun2, Min Lin3, Ke Yu1, Jian Wang1, Dan Duan1, Bo Zheng1, Zhenghui Yang1, Qingsong Wang1.
Abstract
Intracranial aneurysms (IAs) accounts for 85% of hemorrhagic stroke. Genetic factors have been known to play an important role in the development of IAs. A functional CNV (CNV-67048) of human WW domain-containing oxidoreductase (WWOX), which has been identified as a tumor suppressor gene in multiple cancers, was identified to be associated with gliomas risk previously. Here, we hypothesized that the CNV-67048 could also affect susceptibility of IAs. Based on a two-stage, case- control study with a total of 976 patients of IAs and 1,200 matched healthy controls, we found the effect size for per copy deletion was 1.35 (95% CI = 1.16-1.57; Ptrend = 1.18 × 10-4). Compared with the individuals having no deletion, significantly higher risk of IAs was detected for both subjects carrying 1 copy deletion (OR = 1.24, 95% CI = 1.02-1.52) and subjects carrying 2 copy deletion (OR = 1.77, 95% CI = 1.24-2.53). Real-time PCR was used to confirm the abnormal expression of WWOX in tissues of IA patients and influence of genotypes of CNV-67048. The expression level of WWOX in IA tissues was significantly lower than that in corresponding normal tissues (P = 0.004), and the deletion genotypes of CNV-67048 have lower WWOX mRNA levels in both tumor tissues and border tissues (P < 0.01). Our data suggests that the deletion genotypes of CNV-67048 in WWOX predispose their carriers to IAs, which might be a genetic biomarker to predict risk of IAs in Chinese.Entities:
Keywords: SNP; WWOX; gene; intracranial aneurysm; risk factor
Mesh:
Substances:
Year: 2016 PMID: 26910372 PMCID: PMC4941300 DOI: 10.18632/oncotarget.7546
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Characteristics of IAs patients and healthy controls used in this study
| Category | Discovery stage | Validation stage | ||||
|---|---|---|---|---|---|---|
| Cases ( | Controls ( | Cases ( | Controls ( | |||
| Age (yr) | ||||||
| Mean ± SD | 54.0 ± 6.7 | 53.8 ± 7.1 | 0.655 | 53.2 ± 4.1 | 53.7 ± 6.3 | 0.108 |
| Gerder | ||||||
| Male | 167 (41.8%) | 249 (41.5%) | 0.937 | 228 (39.5%) | 233 (38.8%) | 0.792 |
| Female | 233 (58.2%) | 351 (58.5%) | 348 (60.5%) | 367 (61.2%) | ||
| Hypertension | ||||||
| Yes | 240 (60.0%) | 127 (21.2%) | 337 (58.5%) | 120 (20.0%) | ||
| No | 160 (40.0%) | 473 (78.8%) | 239 (41.5%) | 480 (80.0%) | ||
| Ever smoker | ||||||
| Yes | 74 (18.5%) | 86 (14.3%) | 0.078 | 108 (18.8%) | 88 (14.7%) | 0.060 |
| No | 326 (81.5%) | 514 (85.7%) | 468 (81.2%) | 512 (85.3%) | ||
| Ever drinker | ||||||
| Yes | 89 (22.3%) | 121 (20.1%) | 0.428 | 138 (23.9%) | 123 (20.5%) | 0.154 |
| No | 311 (77.7%) | 479 (79.9%) | 438 (76.1%) | 477 (79.5%) | ||
| Body mass index (kg/m2) | 24.2 ± 3.6 | 23.9 ± 3.1 | 0.160 | 24.3 ± 4.1 | 23.9 ± 3.2 | 0.061 |
WWOX gene deletion and risk of IAs in discovery stage
| Genotypes | No. of cases | No. of controls | OR (95% CI) |
|---|---|---|---|
| no deletion | 255 (63.8%) | 431 (71.8%) | 1.00 (reference) |
| 1 copy deletion | 115 (28.8%) | 142 (23.7%) | 1.37 (1.02–1.83) |
| 2 copy deletion | 30 (7.4%) | 27 (4.5%) | 1.88 (1.10–3.21) |
| per copy deletion | 1.43 (1.14–1.80) | ||
| Ptrend |
Adjusted for age, gender, smoking status, and Hypertension.
WWOX gene deletion and risk of IAs in validation stage and the pooled results
| Genotypes | No. of cases | No. of controls | OR (95% CI) |
|---|---|---|---|
| no deletion | 384 (66.7%) | 429 (71.5%) | 1.00 (reference) |
| 1 copy deletion | 147 (25.5%) | 141 (23.5%) | 1.16 (0.89–1.52) |
| 2 copy deletion | 45 (7.8%) | 30 (5.0%) | 1.67 (1.04–2.70) |
| per copy deletion | 1.29 (1.05–1.58) | ||
| Ptrend | |||
| no deletion | 639 (65.5%) | 860 (71.7%) | 1.00 (reference) |
| 1 copy deletion | 262 (26.8%) | 283 (23.6%) | 1.24 (1.02–1.52) |
| 2 copy deletion | 75 (7.7%) | 57 (4.7%) | 1.77 (1.24–2.53) |
| per copy deletion | 1.35 (1.16–1.57) | ||
| P trend |
Adjusted for age, gender, smoking status, and Hypertension.
Figure 1Association between the CNV-67048 and WWOX expression. The relative mRNA levels of WWOX in IA tissues compared with border normal tissues with different genotypes
Figure 2Densitometry measurements from Western blots of WWOX in paired IA tissues and adjacent normal tissues (WWOX in IAs tissues/adjacent normal tissues)